HRT Financial LP sells Profusa shares for $1,234

HRT Financial LP, a 10% owner and director of Profusa, Inc., recently sold shares of the company's common stock for a total of $1,234 between August 5 and August 7, 2026. The purchased shares were sold at prices between $0.942 and $0.946 per share, marking a significant transaction for the company. Additionally, HRT Financial LP acquired shares of Profusa common stock on August 6, 2026, for $873 at a price of $0.943 per share.

As a result of these transactions, HRT Financial LP now beneficially owns 109,288 shares of Profusa, Inc. common stock. The company is currently facing considerable challenges, with shares down 99.9% over the past year, trading at a current price of $0.90. Despite these difficulties, investing experts consider the stock to be undervalued at its current price level.

Profusa has undergone several strategic developments, including the acquisition of the PanOmics multi-omics diagnostics platform from BioInsights LLC, a reverse stock split to maintain compliance with Nasdaq requirements, and the election of Lauren Chung as a Class I director. However, the company's financial health is rated as "WEAK," according to recent analysis.